MMP-2、MMP-14在乳腺癌中的表达及临床意义

目的 探讨基质金属蛋白酶-2（MMP-2）和基质金属蛋白酶-14（MMP-14）在乳腺良性病变、乳腺癌中的表达及其与肿瘤大小、分化程度、腋窝淋巴结转移的关系.方法 应用免疫组织化学PV二步法检测68例乳腺癌组织和24例乳腺良性病变组织中MMP-2和MMP-14蛋白表达情况,并分析其与临床病理参数的关系.结果 MMP-2和MMP-14在乳腺癌中阳性表达率分别为55.9%（38/68）、58.8%（40/68）,在乳腺良性病变中的阳性表达率分别为25.0%（6/24）、16.7%（4/24）,差异均有统计学意义（P＜0.05）;MMP-2和MMP-14的表达与肿瘤大小和腋窝淋巴结转移呈正相关.结论 MMP-2 和MMP-14的表达与肿瘤大小、乳腺癌淋巴结转移有关,可作为评估乳腺癌浸润和转移的生物学指标.     

VEGF-C阳性肥大细胞与乳腺癌淋巴管生成及淋巴结转移的关系

目的 研究乳腺浸润性导管癌中肥大细胞内VEGF-C的表达以探讨MC影响乳腺癌淋巴管生成及淋巴结转移的机制.方法 用免疫组织化学双重染色检查乳腺良性病变和乳腺浸润性导管癌间质中肥大细胞内VEGF-C,用VEGF-C经SP法标记乳腺良性病变和癌组织,用D2-40标记淋巴管并计数.结果乳腺良性病变MC中极少或无蓝黑色VEGF-C颗粒,而乳腺浸润性导管癌MC中均含有较明显,并且前者MC数量(7.80±1.22),明显低于后者MC数量(15.44±2.39),差异有统计学意义(P＜0.01).在浸润性导管癌中,Ⅰ、Ⅱ、Ⅲ级MC数量分别为(10.75±2.61)、(13.70±1.92)、(15.33±0.62),差异亦有统计学意义(P＜0.01).浸润性导管癌有淋巴结转移组的MC数量及癌周边LVD(14.03±2.01,11.21±4.60)明显高于无淋巴结转移组(11.22±0.55,5.78±3.02),差异均有统计学意义(P＜0.01);MC数量与乳腺癌淋巴管数量呈正相关(r=0.18).结论 乳腺癌可诱导MC表达VEGF-C,MC数量与乳腺癌淋巴结转移及淋巴管生成呈正相关性.     

人乳腺癌组织中D2-40标记的微淋巴管密度与血管内皮生长因子C表达的关系

目的 探讨人乳腺癌组织中D2-40标记的微淋巴管密度(LMVD)与血管内皮生长因子C(VEGF-C)表达的关系.方法 收集102例乳腺癌、25例乳腺纤维腺瘤和10例正常乳腺组织标本,采用免疫组化SP法检测D2-40单抗标记的LMVD和VEGF-C蛋白的表达水平,采用原位杂交法检测VEGF-C mRNA的转录水平. 结果 102例人乳腺癌组织中,D2-40标记微淋巴管的阳性率为76.5%,高于乳腺纤维腺瘤组织.癌周组织的LMVD为30.1个微淋巴管/100倍视野,显著高于癌中心区、正常乳腺组织和乳腺纤维腺瘤组织的LMVD (均P＜0.01),且与乳腺癌腋窝淋巴结转移数目明显相关(r=0.964,P<0.01).102例乳腺癌组织中,VEGF-C蛋白和mRNA的阳性表达率分别为55.9%和59.8%,均高于乳腺纤维腺瘤组织(χ2=11.653,P=0.003;χ2=10.345,P=0.006),且与淋巴结转移数目、临床分期、c-erbB-2和p53基因的表达相关(均P<0.05).VEGF-C蛋白和mRNA的表达水平均与D2-40标记的LMVD相关(P<0.05),尤其见于癌周组织中(P<0.01).结论 D2-40单抗标记的LMVD与VEGF-C的表达有密切关系,VEGF-C参与的乳腺癌微淋巴管的生成在乳腺癌淋巴转移中有重要意义.     

ADAM15与MMP-2、MMP-9 mRNA在乳腺癌组织中的表达及意义

目的:探讨ADAM15、MMP-2、MMP-9 mRNA在乳腺癌组织中的表达、与临床病理特征的关系及对乳腺癌转移、预后的影响。方法:采用原位杂交技术检测45例乳腺癌和20例乳腺良性病变中ADAM15、MMP-2和MMP-9 mRNA表达情况。分析ADAM15 mRNA表达与乳腺癌临床病理特征的关系并分析ADAM15 mRNA与MMP-2、MMP-9 mRNA表达的相关性。从TCGA数据库获取乳腺癌转录组数据,通过生物信息学分析相关因素与乳腺癌临床病理特征的关系。结果:ADAM15 mRNA在乳腺癌中高表达,并与乳腺癌淋巴结转移和临床分期密切相关,与患者年龄和肿瘤大小无关。乳腺癌中MMP-2和MMP-9 mRNA阳性率均明显升高,且均与淋巴结转移相关。乳腺癌组织中ADAM15和MMP-2、MMP-9的mRNA表达均呈正相关。生物信息学分析表明ADAM15 mRNA在乳腺癌组织中高表达,其高表达与患者预后密切相关。结论:ADAM15 mRNA在乳腺癌中高表达,与淋巴结转移呈正相关并与患者预后呈负相关,ADAM15 mRNA有可能通过上调MMP-2和MMP-9 mRNA的表达而促进乳腺癌转移。     

乳腺癌患者血清与肿瘤组织VEGF-C表达和淋巴管密度的生物学意义

目的:探讨乳腺癌患者术前外周血清中血管内皮生长因子-C(sVEGF-C)水平及术后肿瘤组织中VEGF-C的表达及淋巴管密度(LVD)的水平与肿瘤淋巴转移的关系。方法:ELISA法检测乳腺癌患者术前外周血清VEGF-C水平,免疫组化SP法检测乳腺癌术后肿瘤组织VEGF-C及抗淋巴管内皮透明质酸受体-1(LYVE-1)的表达,并计算对比分析肿瘤组织LVD。结果:乳腺癌患者sVEGF-C值〔(48.30±23.98)ρg/mL〕较乳腺良性病患者〔(6.26±2.37)ρg/mL〕和健康女性〔(4.72±2.09)ρg/mL〕高,组间比较P值均为0.000;sVEGF-C水平与组织VEGF-C表达正相关,VEGF-C阳性表达者sVEGF-C值为(60.75±11.12)ρg/mL,VEGF-C阴性表达者为(29.86±4.47)ρg/mL,差异有统计学意义,P=0.035;sVEGF-C水平、VEGF-C在组织中的表达分别与乳腺癌患者HER-2表达以及腋淋巴结转移相关,P<0.05。VEGF-C、LVD在乳腺癌组织中的表达较乳腺良性病高,LVD与腋淋巴结转移正相关(P=0.018),VEGF-C与LVD正相关,P=0...     

血管内皮生长因子C蛋白在乳腺癌组织中的表达及其意义

目的:研究血管内皮生长因子C(VEGF-C)蛋白在乳腺癌组织中的表达及意义。方法:采用免疫组化法对60例乳腺癌、12例良性乳腺病变组织中VEGF-C的表达进行检测,探讨其与微血管密度(MVD)、微淋巴管密度(MLD)、增殖细胞核抗原(PCNA)蛋白及临床病理因素之间的相关性。结果:乳腺癌组织中VEGF-C表达水平高于良性乳腺病变组织(u=137.5,P=0.001)。乳腺癌组织中VEGF-C表达与MVD无相关性(P=0.951),而与MLD(r=0.286,P=0.027)及PCNA(r=0.315,P=0.014)有相关性;VEGF-C(r=0.389,P=0.002)、MLD(r=0.335,P=0.009)与患者淋巴结转移状况相关,与其他临床病理因素无相关性。单因素Logistic回归分析显示,高VEGF-C、MLD组发生淋巴结转移的风险分别是低VEGF-C、MLD组的4.059倍(95%CI为1.234～13.349,P=0.021)和3.519倍(95%CI为1.209～10.240,P=0.021)。多因素Logistic回归分析显示,VEGF-C对淋巴结转移的影响独立于MLD。结论:乳腺癌组织中VEGF-C蛋白表达水平升高,VEGF-C在乳腺癌淋巴管生成及淋巴结转移中起重要作用,且它对淋巴结转移的影响独立于MLD。另外,VEGF-C高表达的患者肿瘤细胞的增殖性较强。     

VEGF-C和VEGFR-3对乳腺癌淋巴管生成和淋巴结转移的影响

目的:探讨VEGF-C及VEGFR-3对乳腺癌淋巴结转移的影响。方法:采用免疫组化SP法检测乳腺病、乳腺纤维腺瘤和乳腺癌中VEGF-C及VEGFR-3的表达状态。结果:10例乳腺病及纤维腺瘤VEGF-C均阴性,也无VEGFR-3阳性淋巴管;48例乳腺癌组织VEGF-C阳性率为70.83%(34/48);淋巴结转移者VEGF-C阳性率为92.59%(25/27),显著高于无转移者(42.86%,9/21)(P<0.01)。VEGFR-3阳性淋巴管条数随VEGF-C强度增强而增多。在淋巴结转移者中,VEGFR-3阳性淋巴管条数(6.03)多于无淋巴结转移者(2.01)(P<0.01)。结论:乳腺癌组织中VEGF-C的表达状态与VEGFR-3阳性淋巴管数量及淋巴结转移关系密切。     

环氧合酶-2和血管内皮生长因子-C在乳腺癌组织中的表达及预后生存分析

[目的]评价乳腺癌组织中环氧合酶-2(COX-2)和血管内皮生长因子-C(VEGF-C)在基因及蛋白水平表达,分析两者与乳腺癌患者预后的关系.[方法]采用免疫组化SP法和QRT-PCR法分别检测150例乳腺癌组织中COX-2和VEGF-C在mRNA和蛋白水平表达,并采用Kaplan-meier法和COX风险回归模型分析与乳腺癌预后生存的相关危险因素.[结果]乳腺癌组织中COX-2和VEGF-C在mRNA和蛋白水平率均高于乳腺良性组织(58.8％ vs 41.2％和58.9％ vs 41.1％,P＜0.01).单因素结果显示患者COX-2表达、临床分期、腋窝淋巴结转移、Her-2表达、组织学分级与患者的预后有关;COX多因素分析显示肿瘤大小和腋窝淋巴结是影响乳腺癌患者预后的因素.[结论]乳腺癌患者COX-2和VEGF-C表达上调,乳腺癌组织中肿瘤大小、腋窝淋巴结转移是乳腺癌患者预后的影响因素.     

VEGF-C及其受体VEGFR3在乳腺癌的表达、定位及其在淋巴结转移中的作用

目的:研究VEGF-C及其VEGFR3在乳腺癌组织及癌周组织中的表达情况、分布定位及其在乳腺癌淋巴结转移中的作用。方法:采用免疫组化SP法检测70例患者乳腺癌组织及其癌周组织中VEGF-C和VEGFR3的表达情况,CK19染色检测腋窝淋巴结微转移情况。结果:乳腺癌70例,VEGF-C在乳腺癌组织阳性表达率为78.6%,在癌周组织中的表达率为54.3%(P<0.01)。VEGFR3阳性的脉管数在乳腺癌组织为7.90±5.57,瘤周组织中为10.31±6.52(P<0.01)。VEGFR3的表达主要受乳腺癌细胞VEGF-C表达的影响,两者具有明显的相关性(r=0.66,P<0.05)。乳腺癌淋巴管主要定位于癌周组织及肿瘤间质内,癌巢内未发现成熟淋巴管。VEGF-C在乳腺癌组织内的阳性表达率淋巴结微转移阳性组为87.5%,在淋巴转移阴性组为71.1%,两组差异有统计学意义(P<0.01)。VEGFR3阳性脉管数在乳腺癌瘤周组织中淋巴转移阳性组为12.48±6.51,淋巴转移阴性组为8.47±6.02,两组差异有统计学意义(P<0.01)。结论:VEGF-C在乳腺癌组织肿瘤细胞中呈高表达,而其受体VEGFR3则表达乳腺癌间质和癌周组织的淋巴内皮细胞;乳腺癌新生淋巴管主要定位于癌周及间质;VEGF-C在乳腺癌组织、VEGFR3在癌周组织的表达与乳腺癌淋巴浸润和淋巴结转移密切相关。     

VEGF-C及癌周淋巴管密度与头颈鳞癌颈部淋巴结转移的关系

目的探讨血管内皮细胞生长因子-C（VEGF-C）表达及癌周淋巴管密度（P-LVD）与头颈鳞癌（HNSCC）颈部淋巴结转移的关系。方法采用免疫组化法,检测104例HNSCC组织中VEGF-C及癌周LYVE-1的表达,幷计算P-LVD,分析P-LVD及VEGF-C表达与其临床病理因素的关系。结果 104例HNSCC组织中,VEGF-C阳性表达率显著高于正常头颈部黏膜组织（74.04%vs 0,P〈0.05）。淋巴结转移组VEGF-C阳性表达率高于无淋巴结转移组（P〈0.05）。对LYVE-1标记的淋巴管密度（LVD）分析显示,癌周组织P-LVD高于癌内及正常组织（P〈0.05）,而VEGF-C阳性表达者及颈部淋巴结转移者P-LVD分别显著高于VEGF-C阴性表达者和无颈部淋巴结转移者（P〈0.05）。结论 HNSCC中VEGF-C表达及P-LVD与肿瘤淋巴结转移密切相关,对判断肿瘤侵袭、转移具有一定参考价值。     

Salivary MMP-1, MMP-2, MMP-3 and MMP-13 Levels in Patients with Oral Lichen Planus and Squamous Cell Carcinoma

The aim of present study was to evaluate salivary matrix metalloproteinase-1 (MMP-1) , MMP-2, MMP-3 and MMP-13 levels in patients with oral lichen planus (OLP) and squamous cell carcinomas (SCC) as well as in healthy controls. Thirty cases of OLP (bilateral lesions, papular and reticular lesions, and Wickham lines) clinically and histopathologically (group A), 30 with oral SCCs (group B), and 30 with no history of oral cancer, other lesions or lichen planus (group C) were enrolled at the Department of Oral Medicine School of Dentistry, Zahedan, Iran. Unstimulated whole saliva was collected and laboratory measurement of salivary concentration of MMP-1, MMP-2, MMP-3 and MMP-13 was conducted by immuno-sorbent enzyme-linked methods. Data analysis was performed with Kruskal-Wallis and Mann-Whitney tests and Pearson’s correlation coefficients. In the present study, MMP-2 and MMP-13 levels were higher in oral SCC patients than in OLP cases  and healthy individuals. More research is required to assess MMP links with tumor invasion.     

The MMP-1, MMP-2, and MMP-9 gene polymorphisms and susceptibility to bladder cancer: a meta-analysis

The relationship between matrix metalloproteinase (MMP) polymorphisms and bladder cancer risk has become a hot topic and was studied extensively in recent years, but the results are still controversial. In order to estimate the relationship of MMP polymorphisms and the risk of bladder cancer, we performed this meta-analysis. We conducted a comprehensive search of databases; PubMed, Web of Science, Embase, Chinese Biomedical Literature Database (CBM, Chinese) and Wanfang Database (Chinese) were searched for all case–control studies which mainly study the relationship between MMP-1-1607 1G/2G, MMP-2-1306 C/T, and MMP-9-1562 C/T polymorphisms and the susceptibility of bladder cancer. The association between the MMP polymorphisms and bladder cancer risk was conducted by odds ratios (ORs) and 95 % confidence intervals (95 % CIs). At last, totally five literatures with 1,141 cases and 1,069 controls were contained in the meta-analysis. Among these articles, four articles with 1,103 cases and 1,053 controls were about MMP-1-1607 1G/2G polymorphism and three studies with 839 cases and 775 controls for MMP-2-1306 C/T polymorphism and MMP-9-1562 C/T polymorphism. With regard to MMP-1-1607 1G/2G polymorphism, significant association was found with bladder cancer susceptibility only under recessive model (2G2G vs. 1G2G/1G1G: OR?=?1.44, 95 % CI?=?1.05–1.97, P?=?0.022), and as to the MMP-2-1306 C/T polymorphism, significant association was found with bladder cancer susceptibility only under homozygote model (TT vs. CC: OR?=?2.10, 95 % CI?=?1.38–3.10, P?=?0), but no associations was found between MMP-9-1562 C/T polymorphism and bladder cancer susceptibility. The results suggest that the MMP-2-1306 C/T and MMP-9-1562 C/T polymorphisms are significantly associated with bladder cancer susceptibility, and no associations were found between MMP-9-1562 C/T polymorphism and bladder cancer susceptibility.     

哈萨克族食管癌中MMP-1、MMP-2、MMP-7、TIMP-1和MTA1的表达及其临床病理意义

目的：探讨在新疆哈萨克族食管癌组织中基质金属蛋白酶1、2、7（MMP-1、MMP-2、MMP-7）、基质金属蛋白酶抑制因子1（TIMP-1）和肿瘤转移相关基因1（MTA1）mRNA的表达及其临床意义。方法：采用RT-PCR方法检测75例哈萨克族食管癌标本中MMP-1、MMP-2、MMP-7、TIMP-1和MTA1 mRNA的表达水平,分析其表达与临床病理特征的关系。结果：MMP-1、MMP-2、MMP-7、TIMP-1和MTA1 mRNA在哈萨克族食管癌组织中的表达较正常组织增高,差异均具有统计学意义（P均〈0.05）;且MMP-2、MMP-7、MTA1 mRNA的表达与淋巴结转移有关（P〈0.05）,MMP-1、MMP-7 mRNA的表达与临床分期有关（P〈0.05）;TIMP-1与MMP-1、MMP-7、MTA1的表达呈正相关（r=0.446、0.458、0.333,P均〈0.01）。结论：MMP-1、MMP-2、MMP-7、TIMP-1和MTA1 mRNA表达上调共同参与了哈萨克族食管癌的发生发展过程;MMP-2、MMP-7和MTA1可能是哈萨克族食管癌发生侵袭、转移的主导因素。     

侵袭性垂体腺瘤中Fascin蛋白、MMP-2和MMP-9的表达与研究

目的：垂体腺瘤侵袭性生长的机制还不清楚。本研究旨在检测肌动蛋白结合蛋白（Fascin）及基质金属蛋白酶-2（matrixmetallopmteinasesMMP-2）和基质金属蛋白酶-9（matrix metalloproteinasesMMP-9）在侵袭性垂体腺瘤中的表达水平,分析其与垂体腺瘤的生长侵袭性之间的可能关系。方法：免疫组织化学SP法检测三者在72例垂体腺瘤（侵袭性27例,非侵袭性45例）中的表达水平,统计学分析三者在垂体腺瘤中表达差异性．及与不同临床特征的表达相关性。结果：Fascin蛋白、MMP-2及MMP-9在侵袭性垂体腺瘤的表达水平高于非侵袭性垂体腺瘤（t=3．03,t=3．33,t=2．02,P〈0．05）。三者在垂体腺瘤中表达水平与患者性别无明显相关．与肿瘤有无分泌功能无明显相关,但与肿瘤大小有关铲值分别为8．53,11-31,12．46,P〈0．05）。结论：Fascin蛋白、MMP-2及MMP-9在侵袭性垂体腺瘤中高表达,提示三者可能与垂体腺瘤侵袭性生长密切相关．     

肝癌组织中COX-2、VEGF、MMP-2、MMP-9的表达及相互关系的免疫组化研究

目的　通过检测肝细胞癌组织中COX- 2的表达及其与VEGF、MMP- 2、MMP- 9表达之间的关系,探讨COX- 2在肝细胞癌血管生成和侵袭转移中的作用。方法　应用免疫组化方法检测4 5例肝细胞癌组织中COX- 2和VEGF、MMP- 2、MMP- 9的表达。结果　肝癌组织中COX- 2、VEGF、MMP- 2、MMP- 9表达显著高于肝硬化组织和正常肝组织中的表达;癌组织中COX- 2蛋白的表达与性别、年龄、肿瘤大小、包膜、门静脉癌栓、AFP和组织分化差异均无显著性(P>0 .0 5 ) ;而癌组织中VEGF蛋白表达与分化程度有关;癌组织中MMP- 2、MMP- 9的表达与包膜、门静脉癌栓有关(P<0 .0 5 )。COX- 2与VEGF、MMP- 2、MMP- 9的表达有显著相关性(P<0 .0 5 )。结论　COX-2可能诱导VEGF、MMP- 2、MMP- 9的表达而促进肝细胞癌肿瘤血管的生成和侵袭转移。     

No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population

Previous studies have suggested that the functional polymorphisms in the promoters of matrix metalloproteinases (MMP) genes were associated with the risk of cancers, but no study has ever explored these polymorphisms as risk factors for hepatocellular carcinoma. Recently, we firstly examined whether seven functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12, and MMP-13 have any bearing on the risk of hepatocellular carcinoma, but we found none. In this study, we focused on an additional six MMP polymorphisms, including four functional polymorphisms in the promoters of MMP-7 (A-181G and C-153T) and MMP-8 (C-799T and A-381G), and two nonsynonymous polymorphisms in MMP-10 (A180G) and MMP-21 (C572T). With the polymorphism validation, we found that only MMP-7 A-181G, MMP-8 C-799T, and MMP-21 C572T were polymorphic. These three polymorphisms were then genotyped in 434 patients with hepatocellular carcinoma and 480 controls by PRC-RFLP analysis. The associations between the polymorphisms and hepatocellular carcinoma risk were evaluated while controlling for confounding factors. No significant association with the risk of hepatocellular carcinoma was observed with the three polymorphisms in the overall sample, hepatitis B virus carriers, and non-hepatitis B virus carriers after correction for multiple comparisons. Furthermore, when the analyses were stratified by age, sex, status of smoking and drinking, pack-years of smoking, and family history of hepatocellular carcinoma, there was also no significant association between these polymorphisms and hepatocellular carcinoma risk. Our findings suggest that the polymorphisms MMP-7 A-181G, MMP-8 C-799T, and MMP-21 C572T may not play a major role in mediating susceptibility to hepatocellular carcinoma.     

结肠癌组织MMP-2和MMP-9及VEGF表达临床意义的研究

目的:探讨结肠癌组织中基质金属蛋白酶2(MMP-2)、基质金属蛋白酶9(MMP-9)和血管内皮生长因子(VEGF)的表达及其与肿瘤进展的关系。方法:采用免疫组化SP法检测60例结肠癌组织中MMP-2、MMP-9和VEGF表达情况,并以25例正常结肠组织作为对照。结果:结肠癌组织中MMP-2、MMP-9和VEGF的阳性表达率分别为81.6%、78.3%和90.0%,高于正常结肠组织中的表达,两组比较差异有统计学意义,P<0.05。结肠癌组织中MMP-2、MMP-9和VEGF阳性表达与TNM分期和淋巴结转移相关,差异有统计学意义,P<0.05。结论:MMP-2、MMP-9和VEGF在结肠癌的发生发展和浸润转移中起到了重要的作用,可作为反映结肠癌进展的生物学指标。     

Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer

The main aim of this study was to evaluate the clinical relevance of Gelatinases in colorectal cancer (CRC). Ninety-five CRCs and their paired normal tissues were investigated to detect total levels of MMP-9, MMP-2, and the tissue inhibitors TIMP-1 and TIMP-2. Also, pro-MMP and MMP activity, and potential associations with clinical parameters were estimated. MMP-9, MMP-2 and TIMP-1 levels were greater in CRCs than in normal tissues, differences being significant for MMP-9 and TIMP-1. However, TIMP-2 showed significantly lower levels in tumour samples. Moreover, significant differences in the state of activation between gelatinases were found. TIMP-1 low levels were significantly associated with poor clinical outcome of patients. According to these data, different roles have to be attributed to MMP-2 and MMP-9 in CRC progression. Moreover, TIMP-1 level evaluation emerges as the main prognostic factor in relation to Gelatinases A and B activity in CRC.     

基质金属蛋白酶及其抑制剂在乳腺癌中的表达及其临床意义

背景与目的:基质金属蛋白酶(matrixmetalloproteinase,MMP)与基质金属蛋白酶组织抑制剂(tissueinhibitorofmatrixmetalloproteinase,TIMP)的表达失平衡在肿瘤侵袭、转移过程中起重要作用,但与乳腺癌预后关系的报道少见。本研究探讨MMP-2、MMP-9和TIMP-1、TIMP-2的表达与乳腺癌侵袭、转移和预后的关系。方法:原位杂交、免疫组化检测66例有临床和随访资料的乳腺癌患者的MMP-2mRNA、TIMP-2mRNA和MMP-2、MMP-9、TIMP-1、TIMP-2蛋白表达。统计学分析采用χ2检验、Kaplan-Meier和Cox多因素回归分析。结果MMP-2mRNA、TIMP-2mRNA和MMP-2、MMP-9、TIMP-1TIMP-2蛋白的阳性表达率分别为66.7%(44/66)、65.2%(43/66)和71.2%(47/66)、68.2%(45/66)、40.9%(2766)、69.7%(46/66),其中MMP-2蛋白与MMP-2mRNAMMP-9蛋白及TIMP-2mRNA与TIMP-2蛋白的表达存在显著性正相关(P<0.01);TIMP-1与MMP-9蛋白表达呈负相关(P<0.01)。有淋巴结转移的乳腺癌中MMP-2、MMP-9蛋白表达显著高于无转移者,但TIMP-2mRNA、TIMP-1蛋白表达显著低于无转移者(P<0.05)。乳腺癌中MMP-2mRNA和MMP-9蛋白表达与肿块大小、生存状况有显著性相关(P0.05),此外,MMP-9蛋白表达与临床分期存在正相关性(P<0.01)。绝经和ER表达阴性患者的MMP-2mRNA表达水平增高(P<0.